Overcoming Proteasome Inhibitor-Refractory Multiple Myeloma With Elotuzumab, Bortezomib, Nelfinavir, and Dexamethasone

Multiple myeloma is a common plasma cell malignancy with a median overall survival of fewer than 10 years. Proteasome inhibitors comprise an important part of the treatment regimen for this disease. The present study reports the case of a 57-year-old man who experienced a second relapse of multiple...

Descripción completa

Detalles Bibliográficos
Autores principales: Erath, Alexandra, Patel, Dilan A., Hosack, Eric A., Patanella, James E., Ibach, Daniel M., Kassim, Adetola A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011904/
https://www.ncbi.nlm.nih.gov/pubmed/32095187
http://dx.doi.org/10.14740/wjon1241

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011904/
https://www.ncbi.nlm.nih.gov/pubmed/32095187
http://dx.doi.org/10.14740/wjon1241

Ejemplares similares